Document is current
Any future updates will be listed below
-
Authors
Herbert, Katharine J.
Upstill-Goddard, Rosie
Dreyer, Stephan B.
Rebus, Selma
Pilarsky, Christian https://orcid.org/0000-0002-7968-3283
Debabrata, Mukhopadhyay https://orcid.org/0000-0003-1858-5054
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Biankin, Andrew V.
Froeling, Fieke E. M. https://orcid.org/0000-0002-8653-8164
Chang, David K. https://orcid.org/0000-0002-4821-3078
-
Funding
Funding for this research was provided by:
Cancer Research UK (C29717/A23526)
Cancer Research UK (C51058/A27820)
AstraZeneca
- License Information
-
More Information
Article History
Received: 17 September 2024
Revised: 1 April 2025
Accepted: 1 May 2025
First Online: 29 May 2025
Competing interests
: C.J.L. receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore. Received consultancy, SAB membership or honoraria payments from: FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, ForEx, Ariceum. Has stock in: Tango, Ovibio, Hysplex, Tesselate, Ariceum. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR Rewards to Inventors scheme, and benefits from this scheme associated with patents for PARP inhibitors paid into C.J.Ls. personal account and research accounts at the Institute of Cancer Research. F.E.M.F. receives and/or has received research funding from Astra Zeneca and Sierra Oncology; is part of the Speakers bureau for Servier Oncology; receives travel support from Viatris; and is a member of the advisory board for Astellas and Abbott. D.C. receives and/or has received research funding from AstraZeneca, BMS, Merck, Immodulon; receives consultancy from Immodulon; is part of the speakers bureau and receives travel support from Mylan.
: All methods were performed in accordance with the relevant guidelines and regulations, and access to controlled data used in this investigation was authorised by the International Cancer Genome Consortium Data Access Compliance Office (ICGC DACO), application #DACO-6303 (2021) and #DACO-135 (2022).
